公开(公告)号：EP3463422B1

公开(公告)日：2024-05-22

申请号：EP17805843.4

申请日：2017-05-31

IPC分类号： A61K38/16 ,  A61P3/00 ,  A61P3/06 ,  A61P3/10 ,  A61P3/04 ,  C07K14/02

CPC分类号： A61P3/06 ,  A61P3/04 ,  A61P3/00 ,  A61P3/10 ,  C12N2730/1013320130101 ,  C07K14/005 ,  C12N2730/1012220130101 ,  A61K38/162 ,  A61K45/06

公开(公告)号：EP3903815A1

公开(公告)日：2021-11-03

申请号：EP19901730.2

申请日：2019-11-15

申请人： Grand Theravac Life Science (Nanjing) Co., Ltd.

发明人： LI, Jianqiang ,  GE, Jun ,  REN, Sulin ,  HUANG, Hongying ,  SUN, Jiaojiao ,  SUN, Honglin ,  ZHOU, Tong ,  GU, Yue ,  CHEN, Xiaoxiao ,  ZHOU, Xue

IPC分类号： A61K39/39 ,  A61K39/29 ,  A61K47/26 ,  C07K14/02 ,  A61P31/20

摘要： The present invention discloses a pharmaceutical preparation for treating hepatitis B, a preparation method and use thereof. The pharmaceutical preparation comprises a solution of hepatitis B surface antigen, further a solution of hepatitis B core antigen, and furthermore an oligodeoxynucleotide solution. The pharmaceutical preparation is free of saccharide, has a simple composition and a good antigen stability, without the adverse reactions caused by aluminum adjuvants, and shows good preservation effects in long-term stability experiments.

公开(公告)号：EP3515929B1

公开(公告)日：2021-05-05

申请号：EP17851378.4

申请日：2017-09-11

发明人： WU, Chia-Mao ,  WU, Jiun-Ming ,  LIN, Yi-Chia ,  LEE, Kung-Lung ,  KANG, Chia-Hao ,  CHIANG, Fu-Hsien ,  CHANG, Cheng-Yung ,  CHANG, Wei-Lun ,  LIN, Hsiang-Kai ,  PENG, Chia-Kuan ,  LIN, Wei-Hsiang ,  CHIU, Yi-Tsui

IPC分类号： C07K14/005 ,  C07K14/02 ,  C07K14/705 ,  A61K39/385

公开(公告)号：EP3515929A1

公开(公告)日：2019-07-31

申请号：EP17851378.4

申请日：2017-09-11

申请人： TheVax Genetics Vaccine Co., Ltd.

发明人： WU, Chia-Mao ,  WU, Jiun-Ming ,  LIN, Yi-Chia ,  LEE, Kung-Lung ,  KANG, Chia-Hao ,  CHIANG, Fu-Hsien ,  CHANG, Cheng-Yung ,  CHANG, Wei-Lun ,  LIN, Hsiang-Kai ,  PENG, Chia-Kuan ,  LIN, Wei-Hsiang ,  CHIU, Yi-Tsui

IPC分类号： C07K14/005 ,  C07K14/02 ,  C07K14/705 ,  A61K39/385

公开(公告)号：EP2717910B1

公开(公告)日：2019-01-23

申请号：EP12729450.2

申请日：2012-06-11

申请人： BIOMAY AG

发明人： NIESPODZIANA, Katarzyna ,  FOCKE-TEJKL, Margarete ,  VRTALA, Susanne ,  BANERJEE, Srinita ,  CHEN, Kuan-Wei ,  WEBER, Milena ,  VALENTA, Rudolf ,  MARTH, Katharina

IPC分类号： A61K39/36 ,  C07K14/02

公开(公告)号：EP2732034B1

公开(公告)日：2017-04-26

申请号：EP12733748.3

申请日：2012-07-12

申请人： Transgene SA

发明人： MARTIN, Perrine ,  SILVESTRE, Nathalie ,  MARCHAND, Jean-Baptiste

IPC分类号： C12N9/22 ,  C12N9/12 ,  A61K38/16 ,  C07K14/02 ,  C12N5/10 ,  A61K39/29 ,  A61P31/12

CPC分类号： C12N9/1252 ,  A61K38/00 ,  A61K39/292 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/1276 ,  C12N9/22 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2799/022 ,  C12N2799/023 ,  C12P21/02 ,  C12Y207/07007 ,  C12Y301/26004

摘要： The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.

摘要翻译： 本发明涉及聚合酶HBV突变体多肽，其包含针对聚合酶活性功能性破坏的突变聚合酶结构域和包含此类聚合酶突变体多肽的融合蛋白。 本发明还涉及用于表达所述聚合酶突变多肽的核酸分子和表达载体以及可用于引发针对HBV的免疫应答的组合物，目的是提供针对HBV感染的保护或治疗效果。

公开(公告)号：EP2198020B1

公开(公告)日：2016-04-13

申请号：EP08804169.4

申请日：2008-09-12

申请人： Institut Pasteur ,  INSERM - Institut National de la Santé et de la Recherche Médicale

发明人： DENG, Qiang ,  MICHEL, Marie-Louise

IPC分类号： C12N15/00 ,  C07K14/02 ,  A61K39/245

CPC分类号： C12N15/86 ,  A61K2039/57 ,  C07K14/005 ,  C07K2319/00 ,  C12N2730/10122

摘要： This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then to viral clearance. The vector of the invention, by expression of epitopes derived from common pathogens, by-passes existing tolerance of virus specific T cell responses. The vector will only replicate in virus infected cells.

公开(公告)号：EP2940133A1

公开(公告)日：2015-11-04

申请号：EP13868570.6

申请日：2013-11-28

申请人： The Chemo-Sero-Therapeutic Research Institute ,  Japan as represented by Director General of Agency of National Institute of Infectious Deseases

发明人： YONEMURA, Hiroshi ,  SAKAGUCHI, Masashi ,  IMAMURA, Takashi ,  MORI, Seiichiro ,  KANDA, Tadahito

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K48/00 ,  A61P31/20 ,  A61P35/00 ,  C07K14/02 ,  C07K14/025 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  A61K39/12 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/70 ,  C07K2319/00 ,  C12N2710/20034 ,  C12N2730/10134

摘要： A chimeric protein of HPV-L2 peptide and HBs protein wherein the HPV-L2 peptide is (1) a peptide consisting of the core sequence region of 20 amino acid residues, (2) a peptide inside the core sequence region comprising 6 amino acid residues Gly-Gly-Leu-Gly-Ile-Gly or (3) a peptide consisting of 70 or less amino acid residues obtained by adding an amino acid sequence derived from HPV L2 protein at the N-terminal and/or the C-terminal of the core sequence region; and a vaccine for HPV infection and/or hepatitis B comprising the chimeric protein as an active ingredient. A vaccine comprising the chimeric protein of the present invention is the one that has an increased expression level in a host, an enhanced immune ability (early antibody induction) and a broader spectrum effective for a number of HPV types.

摘要翻译： HPV-L2肽和HBs蛋白的嵌合蛋白，其中HPV-L2肽是（1）由20个氨基酸残基的核心序列区组成的肽，（2）核心序列区内含有6个氨基酸残基的肽 Gly-Gly-Leu-Gly-Ile-Gly或（3）由70个或更少的氨基酸残基组成的肽，其通过在N-末端和/或C末端添加来源于HPV L2蛋白的氨基酸序列而获得 核心序列区; 和用于HPV感染和/或乙型肝炎的疫苗，其包含嵌合蛋白作为活性成分。 包含本发明的嵌合蛋白的疫苗是在宿主中具有增加的表达水平，增强的免疫能力（早期抗体诱导）和对许多HPV类型有效的更广谱的疫苗。

公开(公告)号：EP2935313A1

公开(公告)日：2015-10-28

申请号：EP13814593.3

申请日：2013-12-20

申请人： Vaxin UK Limited

发明人： GEORGES, Bertrand Victor Gilbert ,  BROWN, Carlton Bradley

IPC分类号： C07K14/02 ,  A61K39/29 ,  C12N7/00 ,  A61K39/12 ,  A61P35/00

CPC分类号： A61K39/292 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/55 ,  A61K2039/572 ,  A61K2039/58 ,  A61K2039/60 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2730/10171

摘要： A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

公开(公告)号：EP1660125B1

公开(公告)日：2015-05-06

申请号：EP04764564.3

申请日：2004-08-27

申请人： Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH

发明人： MELBER, Karl

IPC分类号： A61K39/12 ,  A61K39/29 ,  C07K14/02 ,  C07K14/005 ,  C12N15/85

CPC分类号： C12N15/8509 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/57 ,  C07K14/005 ,  C12N2730/10122 ,  C12N2730/10134